Lactobacilli and bifidobacteria derived from infant intestines may activate macrophages and lead to different IL-10 secretion

Liang, Huijing; Luo, Zihao; Miao, Zhonghua; Shi, Xi; Li, Ming; Zhang, Xuguang; Ze, Xiaolei; Chen, Qiwei; He, Fang

doi:10.1080/09168451.2020.1811948

Cited by 12 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 29 , 30 We describe here a restoration of the gut microbiota in the preterm neonate towards a composition rich in bifidobacteria, which have been proved effective in reducing the intestinal inflammatory state by regulating pro- and anti-inflammatory cytokines. 31 , 32 The present results corroborate those of previous studies documenting that specific probiotics may transiently colonize the infant gut, modulate the preterm child´s gut microbiota composition, 33 and extend these to the documentation of the optimal mode of administration.…”

Section: Discussionsupporting

confidence: 90%

The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial

et al. 2023

View full text Add to dashboard Cite

Background Preterm children with their aberrant gut microbiota and susceptibility to infections and inflammation constitute a considerable target group for probiotic therapy to generate the age-appropriate healthy microbiota. Methods 68 preterm neonates were randomized into five intervention groups: Beginning from the median age of 3 days, 13 children received Lactobacillus rhamnosus GG (LGG) directly orally, and 17 via the lactating mother. 14 children received LGG with Bifidobacterium lactis Bb-12 (Bb12) orally, and 10 via the lactating mother. 14 children received placebo. The children’s faecal microbiota was assessed at the age of 7 days by 16S rRNA gene sequencing. Results The gut microbiota compositions of the children directly receiving the probiotic combination (LGG + Bb12) were significantly different from those of the children receiving the other intervention modes or placebo (p = 0.0012; PERMANOVA), the distinction being due to an increase in the relative abundance of Bifidobacterium animalis (P < 0.00010; ANCOM-BC), and the order Lactobacillales (P = 0.020; ANCOM-BC). Conclusion The connection between aberrant primary gut microbiota and a heightened risk of infectious and non-communicable diseases invites effective microbiota modulation. We show that the direct, early, and brief probiotic intervention of LGG + Bb12 109 CFU each, is sufficient to modulate the gut microbiota of the preterm neonate. Impact Preterm children have a higher risk of several health problems partly due to their aberrant gut microbiota. More research is needed to find a safe probiotic intervention to modify the gut microbiota of preterm children. The maternal administration route via breast milk might be safer for the newborn. In our study, the early and direct administration of the probiotic combination Lactobacillus rhamnosus GG with Bifidobacterium lactis Bb-12 increased the proportion of bifidobacteria in the preterm children’s gut at the age of 7 days, but the maternal administration route was not as effective.

show abstract

Section: Discussionsupporting

confidence: 90%

The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, some studies reported that TLR2 −/− mice have less intestinal damage and inflammation than WT mice [76,77]. In addition, et al revealed that bifidobacterial and lactobacilli induced IL-10 secretion in macrophages by activating TLR2 and MyD88 pathways, conferring a protection in hosts suffering from inflammatory diseases [78]. Another group observed TLR2mediated secretion of IL-10 and immune suppression in response to phagosome-confined Listeria monocytogenes [79].…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus murinus alleviate intestinal ischemia/reperfusion injury through promoting the release of interleukin-10 from M2 macrophages via Toll-like receptor 2 signaling

Deng

Zhao

et al. 2022

Microbiome

View full text Add to dashboard Cite

Background Intestinal ischemia/reperfusion (I/R) injury has high morbidity and mortality rates. Gut microbiota is a potential key factor affecting intestinal I/R injury. Populations exhibit different sensitivities to intestinal I/R injury; however, whether this interpopulation difference is related to variation in gut microbiota is unclear. Here, to elucidate the interaction between the gut microbiome and intestinal I/R injury, we performed 16S DNA sequencing on the preoperative feces of C57BL/6 mice and fecal microbiota transplantation (FMT) experiments in germ-free mice. The transwell co-culture system of small intestinal organoids extracted from control mice and macrophages extracted from control mice or Toll-like receptor 2 (TLR2)-deficient mice or interleukin-10 (IL-10)-deficient mice were established separately to explore the potential mechanism of reducing intestinal I/R injury. Results Intestinal I/R-sensitive (Sen) and intestinal I/R-resistant (Res) mice were first defined according to different survival outcomes of mice suffering from intestinal I/R. Fecal microbiota composition and diversity prior to intestinal ischemia differed between Sen and Res mice. The relative abundance of Lactobacillus murinus (L. murinus) at the species level was drastically higher in Res than that in Sen mice. Clinically, the abundance of L. murinus in preoperative feces of patients undergoing cardiopulmonary bypass surgery was closely related to the degree of intestinal I/R injury after surgery. Treatment with L. murinus significantly prevented intestinal I/R-induced intestinal injury and improved mouse survival, which depended on macrophages involvement. Further, in vitro experiments indicated that promoting the release of IL-10 from macrophages through TLR2 may be a potential mechanism for L. murinus to reduce intestinal I/R injury. Conclusion The gut microbiome is involved in the postoperative outcome of intestinal I/R. Lactobacillus murinus alleviates mice intestinal I/R injury through macrophages, and promoting the release of IL-10 from macrophages through TLR2 may be a potential mechanism for L. murinus to reduce intestinal I/R injury. This study revealed a novel mechanism of intestinal I/R injury and a new therapeutic strategy for clinical practice.

show abstract

“…In this study, compared with WT mice, TLR2 −/− mice fail to produce a protective response after I/R. In addition, Liang et al revealed that bi dobacterial and lactobacilli induced macrophages to secrete IL-10 by activating TLR2 and MyD88 pathways, conferring a protective effect in hosts suffering from in ammation diseases [46]. Another group found that TLR2-mediated secretion of IL-10 and immune suppression in response to phagosome-con ned Listeria monocytogenes [47].…”

Section: Discussionmentioning

confidence: 55%

Lactobacillus Murinus Alleviates Intestinal Ischemia/Reperfusion Injury Through Promoting the Release of Interleukin-10 From M2 Macrophages via Toll-like Receptor 2 Signaling

Deng

Zhao

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundIntestinal ischemia/reperfusion (I/R) injury has high morbidity and mortality. Gut microbiota is one of the potential key factors affecting intestinal I/R injury. Different populations exhibit different sensitivities to intestinal I/R injury, but whether this is related to differences in gut microbiota is unclear. Here, to elucidate the interaction between the gut microbiome and intestinal I/R injury, we conducted 16S rRNA gene sequencing and fecal microbiota transplantation experiment in an I/R mouse model. Toll-like receptor 2 (TLR2)-deficient mice, interleukin-10 (IL-10)-deficient mice as well as the transwell co-culture system of small intestine organoids and macrophages were used to explore the potential mechanism of bacteria attenuating intestinal I/R injury.ResultsThe intestinal I/R-sensitive (Sen) and resistant (Res) mice were first defined according to different survival outcomes of mice suffering from intestinal I/R. Fecal microbiota composition and diversity prior to intestinal ischemia were different between in Sen and Res mice. The relative abundance of Lactobacillus murinus (L. murinus) at the species level was higher in Res mice than in Sen mice, and the fold change was the largest. Clinically, the abundance of L. murinus in preoperative feces of patients undergoing cardiopulmonary bypass surgery was closely related to the degree of intestinal I/R injury after surgery. Treatment with L. murinus significantly prevented from intestinal I/R-induced intestinal injury and improved the survival of mice, which depends on the participation of macrophages. Further, in vivo and vitro experiments indicated that L. murinus promoted the release of IL-10 from M2 macrophages via activating TLR2 signaling to alleviate intestinal I/R injury. ConclusionGut microbiome is involved in the postoperative outcome of intestinal I/R. L. murinus promotes the release of IL-10 from M2 macrophages through TLR2 signaling to alleviate intestinal I/R injury, revealing a novel mechanism of intestinal I/R injury and new therapeutic strategy for clinical practice.

show abstract

Lactobacilli and bifidobacteria derived from infant intestines may activate macrophages and lead to different IL-10 secretion

Cited by 12 publications

References 45 publications

The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial

The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial

Lactobacillus murinus alleviate intestinal ischemia/reperfusion injury through promoting the release of interleukin-10 from M2 macrophages via Toll-like receptor 2 signaling

Lactobacillus Murinus Alleviates Intestinal Ischemia/Reperfusion Injury Through Promoting the Release of Interleukin-10 From M2 Macrophages via Toll-like Receptor 2 Signaling

Contact Info

Product

Resources

About